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Background. Hepatitis C virus (HCV) can be purified from serum of chronically-infected patients in the form of Lipo-Viro-
Particles (LVP), which are triglycerid-rich lipoprotein-like particles containing viral RNA and proteins. Since LVP is a constant
feature of chronically infected patients, we asked whether purified LVP could interfere with the immune response by acting
directly on dendritic cell (DC) function. Methods and Findings. We have analyzed the impact of LVP on the maturation
monocyte-derived DC induced by TLR3 or TLR4 ligands. Following incubation with LVP, immature DC supported weak transient
HCV-RNA replication and type I IFN synthesis. This, however, did not lead to viral particle production nor to maturation of DC.
LVP-treatment prior to TLR3 stimulation by polyI:C only enhanced the secretion of IL-12, IL-6 and TNFa yielding typical mature
DC. In contrast, LVP-treated DC activated by the TLR4 ligand LPS yielded phenotypically mature DC with reduced capacity to
secrete both pro- and anti-inflammatory cytokines. Their ability to stimulate allogeneic T lymphocytes was strongly affected
since activated T cells produced IL-5 and IL-13 instead of IFNc. Addition of IFNa prevented the effect of LVP on DC function.
Restoration of IFNc secretion by T cells was obtained by blocking ERK activation in DC, while induction of IL-5 and IL-13
secretion was inhibited by blocking the p38-MAPK pathway in DC. Conclusions. LVP can interfere with TLR4-triggered
maturation of DC, inducing a shift in DC function that stimulates Th2 cells instead of Th1, by a mechanism that is ERK- and p38-
MAPK-dependent. The effect of LVP on DC polarization was reversed by IFNa, providing an additional rationale for the
interferon therapy of chronically-infected patients. By acting on TLR4 pathway with LVP, HCV may thus exploit a natural
protective mechanism of the liver and the intestine normally used to control inflammation and immunity to commensal
microorganisms.
Citation: Agaugue ´ S, Perrin-Cocon L, Andre ´ P, Lotteau V (2007) Hepatitis C Lipo-Viro-Particle from Chronically Infected Patients Interferes with TLR4
Signaling in Dendritic Cell. PLoS ONE 2(3): e330. doi:10.1371/journal.pone.0000330
INTRODUCTION
HCV infection is a major public health problem because of the high
incidence of chronicity which often leads to liver cirrhosis and
hepatocellular carcinoma [1]. HCV is a single stranded RNA virus
which has remained poorly characterized due to the lack of an
efficient cell culture system and purification procedure but the
replicon systems now allowing production of viral particles offer
promising tools to help understanding the biology of this virus [2–4].
ThedensityofplasmaHCV-RNAcontainingparticlesissurprisingly
heterogeneous and the unusually low density of some of these
particlessuggestsan associationofthe virus withplasmalipoproteins.
HCV may simplybind to circulating lipoproteins but aninterference
occurring during lipoprotein synthesis by infected hepatocytes may
alsoleadtothegenerationofahybrid-viruslikeparticle.Oneformof
HCV-RNA containing structures with low density has indeed been
purified from plasma of chronically-infected patients [5–8]. These
particles named Lipo-Viro-Particles (LVP) appeared as large
lipoprotein-like structures enriched in triglycerides containing
internal viral capsids and carrying viral envelope proteins at their
surface [9]. These particles can enter human hepatocytes in vitro
through the interaction of apolipoprotein B and E with lipoprotein
receptors. The presence of LVP is a constant feature of chronicity
but their role in HCV infection and disease progression remains
elusive. Quasi-species analysis, the presence of HCV proteins in the
enterocytes of chronically-infected patients and the biochemical
composition of LVP strongly suggest that LVP can originate from
both the liver and the intestine [5,6,10,11].
Beside the intriguing question of the generation of such a viral
structure, LVP is of particular interest because of their lipoprotein
nature and the complex mixture of lipids it can contain. Many
immunomodulatory properties have been assigned to native and
modified lipids and the immunological properties of native and
oxidized lipoproteins are influenced by their content in anti- and
pro-inflammatory lipids [12–14]. For instance, we and others have
shownthatoxidativemodificationsoflipoproteinscanbedetectedby
dendritic cells (DC) and lipids generated during oxidation can either
induce or inhibit DC maturation [15–19]. Many lipids have also
been shown to interfere with bacteria LPS and Toll-like receptor
(TLR) 4 signaling. The overall data from the literature suggest that
natural modification of lipids leads to the formation of both positive
and negative regulators of adaptive immune responses.
These immunomodulatory properties of lipids have been
exploited by many parasites to subvert and escape the immune
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inhibits IL-12 production by DC stimulated with IL-1 and TNFa
and induces IL-10-secreting regulatory T cells by a TLR2-
dependent process. By contrast, DC treated with the inflammatory
cocktail and phosphatidylserine from eggs of the parasite induce
IL-4-secreting Th2 cells [20]. High amounts of HETE have been
detected in red blood cells parasitized by Plasmodium falciparum,
interfering with activation of monocytes and maturation of DC
induced by LPS [21,22]. The excretory-secretory product-62 (ES-
62) is a phosphorylcholine-substituted secreted glycoprotein of
Acanthocheilonema viteae that exerts immunomodulatory func-
tions via TLR-4. In vitro and in vivo exposure of macrophages,
DC and their precursors to ES-62 renders the cells unable to
respond normally to LPS, polarizing their differentiation towards
a Th2/anti-inflammatory phenotype [23,24].
There are increasing evidences showing that viruses can interact
with TLR signaling. Viral components can either bind to TLR
and activate their signaling pathway or block TLR function by
interfering with intracellular intermediates. Double-stranded RNA
(dsRNA) is generated during viral replication and TLR3 activation
can be triggered by the synthetic analog of dsRNA polyinosine-
deoxycytidylic acid (poly I:C). Moreover, the HCV serine protease
NS3/4A can specifically degrade the adaptor protein TRIF (Toll-
interleukin 1 receptor domain–containing adaptor inducing IFNb)
resulting in inhibition of TLR3 signaling in HeLa cells containing
replicating HCV RNA [25]. Although TLR4 is well-known for its
capacity to detect bacterial lipopolysaccharide (LPS), this receptor
can also recognize viral components such as the fusion protein
from respiratory syncytial virus (RSV) [26] and the envelope
protein of mouse mammary tumor virus (MMTV) [27]. TLR4 is
important for clearing RSV infection [28] whereas MMTV
maintenance depends on TLR4 stimulation by the virus that
induce immunoregulatory IL-10 secretion [29].
We have thus studied the reactivity of DC to LVP and its
consequences on cellular maturation induced by different TLR3
and TLR4 ligands. It appeared that LVP induced a TLR4
signaling defect involving ERK and p38-MAPK pathways that
can be overcome by alpha interferon (IFNa).
MATERIALS AND METHODS
Patients
Blood samples were obtained from volunteers attending the Liver
Unit at Necker Hospital (Paris, France). Blood was collected
during a therapeutical bleeding prescribed by Dr. S. Pol (Service
d’hepatologie, Ho ˆpital Cochin, Paris). Written informed consent
was obtained from each patient in agreement with the institutional
review board of the Etablissement Francais du sang and the ethical
guidelines of the Declaration of Helsinki. Chronically-infected
patients have not been given antiviral therapy for more than six
months. Viruses were of genotypes 1a, 1b, 2a, 3 and 4. Similar
results were obtained irrespectively of genotype.
LVP purification
LVP was purified by density gradient ultracentrifugation and
immunocapture with microbeads as described [6]. Briefly, the
density of plasma (1.0063 g/ml) was raised to 1.055 g/ml using
NaBr (Sigma-Aldrich, St Quentin-Fallavier, France). After centri-
fugation at 100000 rpm, 4 h at 4uC on a TL100 centrifuge
(Beckman Instruments, Gagny, France), the low density fraction
(density between 1.0063 and 1.055 g/ml corresponding to
densities of Very Low Density Lipoprotein (VLDL), Intermediate
Density Lipoprotein (IDL) and Low Density Lipoprotein (LDL))
was collected, extensively dialyzed at 4uC against 150 mM NaCl/
0.24 mM EDTA pH 7.4 and filtered through 0.22 mm-poresize
filters (Millipore S.A., St Quentin, France). Immunoglobulin-
coated LVP were then purified by incubating the low density
fraction with protein A-coated microbeads (Miltenyi Biotec, Paris,
France) and by separation on a magnetic column (Miltenyi Biotec).
LVP was collected in Dulbecco’s Modified Eagle Medium
(DMEM) containing 0.2% BSA (Invitrogen, Cergy Pontoise,
France) and stored at 4uC until use.
The light fraction at the same density than LVP (1.0063,
d,1.055 g/ml) was purified from plasma of healthy individuals
and immunoprecipitated with an anti-apolipoprotein B antibody
(Calbiochem, La Jolla, CA) and protein A-microbeads as described
above and used as control (IP-LP for immunoprecipitated
lipoparticles).
HCV-RNA quantification
RNA was extracted from 1.5610
5 cells using RNeasy mini kit
(Qiagen, Courtaboeuf, France), and from LVP and culture super-
natants using Nucleospin RNA virus kit (Macherey-Nagel, Hoerdt,
France). Known amounts of HCV-RNA were mixed with control
cells or supernatants, extracted as samples and used to establish the
standardcurve.HCV-RNAwasthenquantifiedbyreal-timePCRof
the 59-HCV noncoding region as described [6,30].
Monocyte and lymphocyte purification
Human peripheral blood from healthy donors was obtained from
the Etablissement Franc ¸ais du Sang (Lyon, France). Mononuclear
cells were isolated by density gradient centrifugation using Ficoll-
Hypaque, and then centrifuged on a 50% Percoll solution
(Amersham Biosciences, Uppsala, Sweden). Two fractions were
recovered: monocytes were purified from the light density fraction
and T lymphocytes from the high density fraction by immuno-
magnetic depletion (Dynal Biotech, Oslo, Norway) using a cocktail
of mAb: anti-CD19 (4G7 hybridoma; provided by Dr Ron Levy),
anti-CD3 (OKT3; American Type Culture Collection, Manassas,
VA) and anti-CD56 (NKH1; Beckman Coulter, Fullerton, CA) for
monocytes; anti-CD19 (4G7), anti-CD56 (NKH1), anti-CD14
(RMO52), anti-CD16 (3G8) and anti-glycophorin A (11E4B7.6)
(all from Beckman Coulter) for T lymphocytes. Monocytes were
.90% pure as assessed by CD14 labeling and T lympho-
cytes.95% pure as assessed by CD3 labeling.
Generation and treatment of DC
Monocytes (10
6 cells/ml) were differentiated at 37uC under 5%
CO2 to immature DC (iDC) in complete RPMI 1640 medium
(Invitrogen) supplemented with 10% FCS, 50 ng/ml human
recombinant granulocyte-macrophage colony-stimulating factor
(GM-CSF) and 62.5 ng/ml human recombinant IL-4 (all from
Abcys, Paris, France). For the study on iDC, LVP (4 copies of
HCV-RNA/cell) were added at day (d) 5 (for a 48 h-incubation) or
at d 6 (for a 24 h-incubation) of differentiation. Control iDC were
obtained without any treatment and were CD14
2 CD1a
+. Cells
and supernatants were collected at d 7. To induce DC maturation,
LPS (1 mg/ml; Escherichia coli; Sigma) or polyI:C (2 mg/ml,
Amersham Biosciences) were always added at d 6 for 24 h. To
analyze the impact of LVP on DC maturation, cells were treated
with LVP (4 HCV-RNA copies/cell) either at d 5 (24 h before
maturation) or at d 6 (2 h before maturation). In some
experiments, IFNa (Intron A, 500 IU/ml; Schering-Plough,
Kenilworth, NJ) or IFNb (500 IU/ml; PBL Biomedical Labora-
tories, Piscataway, NJ) were added concomitantly to LVP at d 5.
When indicated, cells were pre-incubated with an inhibitor of the
Mitogen-activated protein kinase/extracellular signal to regulated
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or an inhibitor of p38-MAPK (25mM SB203580; Biomol) 30 min
before LVP treatment at d 5. Control mature DC (mDC) were
obtained at d 7 after addition of 1 mg/ml LPS or 2 mg/ml polyI:C
at d 6. All cells and culture supernatants were collected at d 7.
Phenotype
Phenotype was analyzed by flow cytometry on a FACSCalibur (BD
Biosciences, Franklin Lakes, NJ) using FITC-conjugated anti-CD14,
-HLA-DR, -CD80, and phycoerythrin (PE)-conjugated anti-CD1a,
-CD86, -CD83 and -CD40 (all from Beckman Coulter).
Endocytosis
Cells were resuspended at 10
6 cells/ml incomplete RPMI/10% FCS
medium and were incubated at 37uC for 30 min with 1 mg/ml
FITC-T40-dextran (Sigma-Aldrich). Internalization was stopped on
ice with cold phosphate-buffered saline (PBS) containing 1% BSA
and 0.05% NaN3. Cells were washed three times at 4uCi nt h i sb u f f e r
and the amount of probe internalized was measured by flow cyto-
metry. Control was obtained by incubation of cells for 30 min at 4uC.
Cytokine assay
Culture supernatants were stored at 280uC until use. Cytokine-
specific enzyme-linked immunosorbent assay (ELISA) kits were
from Pierce (Rockford, IL) except for IL-12p40 that was from
Biosource International (Camarillo, CA).
Mixed Leukocyte Reaction (MLR)
Primary MLR were conducted in 96-well flat-bottom culture
plates. DC recovered at d 7 were extensively washed and
resuspended in complete RPMI/10% FCS. These cells were then
cocultured with 2610
5 allogeneic T cells in a final volume of
200 ml at DC/T cell ratios ranging from 1/10 to 1/40. Culture
supernatants were recovered after 2 d of coculture for IL-2
quantification and after 4 d of coculture for the measurement of
IL-4, IL-10, IL-5, IL-13 and IFNc by sandwich ELISA (Pierce).
Type I IFN detection
Type I IFN was measured by a biological assay as described [31].
Type I IFN level in culture supernatants was quantified by
determining the protection of bovine kidney cells against the
cytopathic effect of vesicular stomatitis virus. Titers were
compared to a standard recombinant IFN (Intron A).
Immunofluorescence
DC were layered on a microscope slide after cytospin at 500 rpm,
5 min. After fixation by 4% paraformaldehyde and permeabiliza-
tion by PBS/0.1% triton X100, cells were washed three times in
PBS/0.2% BSA and incubated with the primary antibody
(biotinylated F(ab9)2 fragment from 4F3H2 mAb, bioMe ´rieux
SA, Marcy l’Etoile, France) for 30 min. Slides were washed three
times with PBS/0.2% BSA and incubated for 30 min with FITC-
conjugated streptavidine. After three washes in PBS/0.2% BSA
and a final wash in distilled water, slides were mounted in
fluorescent mounting medium (Dako, Glostrup, Denmark).
RESULTS
Effect of LVP on immature DC
The capacity of LVP to infect iDC was first examined. Lipoproteins
can be purified from the plasma by ultracentrifugation on density
gradient. In HCV-infected patients, the lipoprotein fraction contains
LVP that are low density lipoproteins containing viral capsids. These
particles are naturally coated with antibodies allowing their
separation from normal lipoproteins by protein A-microbeads.
These purified LVP were used throughout this paper. iDC were
cultured with 4 HCV-RNA copies/cell for 24 and 48 h before
harvesting of supernatants and cells. Quantification of intracellular
HCV-RNAwasperformedbyreal-timePCRaspreviouslydescribed
[6,30]. Figures 1a and 1b show that LVP entry into iDC can be
followed by amplification of HCV-RNA which peaked at 24 h and
decreased at 48 h post-infection, suggesting that RNA does not
persistincells.HCVnegativestrand couldalso be detected in cellsby
real time PCR and its identification was confirmed by sequencing
(data not shown) [32]. However, detection of HCV negative strand
was much less efficient, suggesting that RNA amplification can occur
but is not a major event. LVP entry is accompanied by protein
synthesis as exemplified by positive NS5A nonstructural protein
staining ofmostDC(figure1c). Meanwhile, HCV-RNA disappeared
from the supernatant indicating that no viral particle was released by
infected iDC (figure 1b). LVP induced type I IFN production by DC
with a kinetic similar to the RNA quantification curve with a peak at
24 h and a decrease at 48 h (figure 1d).
LVP does not induce DC maturation
To investigate the biological functions of LVP, the reactivity of
iDC to LVP was analyzed at the phenotypical and functional
levels. The phenotype of DC cultured with LVP for 24 h and 48 h
was identical to that of control iDC with comparable level of HLA
and costimulatory molecules (figure 2a). Endocytic capacity of
LVP-incubated iDC was not reduced compared to control iDC
and secretion of IL-12, IL-6, TNFa and IL-10 was not significantly
modified (figure 2b and c). LVP addition did not affect the viability
of DC (data not shown). Thus, incubation of LVP with DC for 24
or 48 h did not induce DC maturation, suggesting that LVP does
not provide a maturation signal for DC or that some viral
component interferes with the maturation process.
Influence of LVP infection on DC maturation
A number of viruses have been reported to impair DC maturation
[33]. We thus investigated the effect of LVP on the maturation
induced by LPS or polyI:C to determine whether LVP could
interfere with the maturation process. LPS was used as a TLR4
ligand whereas polyI:C was used as a prototype of TLR3
activation. iDC were treated with LPS or polyI:C at d 6 of
differentiation and LVP were added 24 h before the maturation
stimulus. Phenotypic and functional analyses were performed 24 h
after the induction of maturation. Figure 3a shows that LPS-
induced upregulation of HLA-DR and costimulation molecules
was not affected by the presence of LVP. All cells were CD14
2
CD1a
+ (data not shown). In contrast, DC which were treated with
LVP 24 h before LPS addition showed a decreased secretion of
IL-12 (50%), IL-6 (50%) and IL-10 (65%) while TNFa secretion
was maintained (figure 3b).
LVP-treated DC stimulated by polyI:C showed slight increase
of expression of CD83 and CD86 compared to polyI:C-activated
DC, while the expressions of HLA-DR, CD80 and CD40 were
comparable (figure 3c). LVP-treated DC stimulated by polyI:C
showed increased secretions of IL-6, IL-12 and TNFa whereas no
IL-10 was secreted. Nevertheless, the levels of secretion were lower
compared to those induced by LPS (figure 3d).
Thus these data suggest that LVP interferes with the TLR4 and
TLR3 signaling pathways involved in cytokine secretion, resulting
in different profiles of production. TLR4 stimulation is impaired
while TLR3 pathway seems hyperreactive.
HCV Alters TLR4 Signaling
PLoS ONE | www.plosone.org 3 March 2007 | Issue 3 | e330Figure 1. Effect of LVP on immature dendritic cells. (a, b) iDC were incubated for the indicated times with 6610
5 HCV-RNA copies (4 HCV-RNA
copies/cell). At d 7, HCV-RNA was extracted from cells (a) and supernatants (b) and quantified. Data represent mean copy number/well6sd from
triplicates of one representative experiment out of three. (c) NS5A was detected after cytospin of fixed DC (48 h non-treated or LVP-treated DC) using
biotinylated 4F3H2 monoclonal antibody and FITC-conjugated streptavidin. Left: 48 h-non treated DC; middle and right: 48 h LVP-treated DC
observed in fluorescence microscopy (middle) and in confocal microscopy (right). (d) Type I IFN production was measured by a biological assay in
supernatants of non-treated, 24 h or 48 h LVP-treated DC. Titers are expressed as IU/ml with reference to a recombinant IFN. Data represent
mean6sd from four independent experiments.
doi:10.1371/journal.pone.0000330.g001
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Th2-oriented response
LVP-treated DC matured with LPS or polyI:C were further tested
for their ability to stimulate an allogeneic T cell response in MLR
experiments. 24 h LVP-treated DC matured with LPS are able to
stimulate IL-2 secretion by allogeneic T cells similarly to control
mDC. However, in addition to a decreased cytokine production,
LPS addition on 24 h LVP-treated DC yielded cells that failed to
induce IFNc production by allogeneic T cells (figure 4a). Although
HCV-RNA and protein are present during the early steps of the
MLR corresponding to 48 h LVP-treated DC (figure 1a, b), direct
Figure 2. LVP incubation of iDC does not induce maturation. Cells were incubated with LVP as in figure 1. Analysis were performed on non-treated
iDC, 24 h and 48 h LVP-treated iDC. (a) Phenotype of non-treated iDC (filled profile), 24 h LVP-treated iDC (thick line) and 48 h LVP-treated iDC (thin
line). Representative results of one experiment out of three. (b) Endocytic capacity of non-treated DC (opened bars), 24 h LVP-treated iDC (hatched
bars) and 48 h LVP-treated iDC (filled bars). Mean fluorescent intensities were normalized to 100% uptake for non-treated control iDC. Data from one
representative experiment out of three. (c) Cytokine secretion in the supernatant of 24 h (hatched bars) and 48 h LVP-treated DC (filled bars)
compared to non-treated iDC (opened bars). Data represent mean secretion6sd from four independent experiments.
doi:10.1371/journal.pone.0000330.g002
HCV Alters TLR4 Signaling
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DC/T cell coculture (data not shown). Since Th2 responses have
been observed in some HCV-chronically infected individuals and
to further evaluate the functional potential of LVP-treated DC, we
analyzed the level of various cytokines in MLR supernatants. No
IL-4 or IL-10 could be detected in cocultures of T cells and LVP-
infected DC treated with LPS (data not shown). In contrast,
increased IL-5 and IL-13 levels were detected in the supernatants
of coculture of T cells and DC treated with LVP 24 h before LPS
(figure 4a). Thus, DC incubated with LVP prior to LPS treatment
stimulate T cells to secrete IL-5 and IL-13 and low amounts of
IFNc whereas control LPS-treated DC activate T cells to secrete
IFNc with low amounts of IL-5 and IL-13.
In contrast to what is observed after LPS activation of LVP-
treated DC, treatment of DC with LVP before polyI:C activation
did not inhibit the production of IFNc by T cells, therefore
correlating to the pro-inflammatory cytokines secreted by these
DC (figure 3d, 4b). IL-13 production was still slightly increased but
not IL-5 (figure 4b). Neither IL-4 nor IL-10 could be detected in
the same supernatants (data not shown).
These data suggest that LVP interferes with the TLR4 signaling
to induce a Th2 shift in the T cell response, whereas TLR3
activated DC still induce a Th1 response.
Purified native lipoproteins do not induce a Th2-
biased maturation following TLR4 stimulation
Although there is no equivalent of LVP particle in healthy donors,
we tested the impact lipoproteins prepared as similarly as possible
as LVP. They were prepared from the light fraction of lipoproteins
from healthy individuals coated with anti-apolipoprotein B
antibodies and purified by magnetic positive selection with protein
A-coated microbeads (see materials and methods section). The
effect of these non-infected immunoprecipitated lipoproteins
named IP-LP (for immunoprecipitated lipoparticles) was analyzed
on maturation of DC induced by LPS as for LVP (figure 5).
Control IP-LP did not inhibit the induction of a mature phenotype
(figure 5a) and did not affect cytokine production induced by LPS
(figure 5b). In contrast to LVP, control IP-LP did not inhibit the
ability of LPS-treated DC to induce IFNc production and did not
increase their potential to stimulate IL-5 and IL-13 secretion by
allogeneic T cells (figure 5c).
IFNa can reverse the effect of LVP on DC
polarization
IFNa is an anti-viral cytokine that is currently given to HCV
chronically-infected patients with a certain level of success. We
Figure 3. LVP treatment of iDC inhibits maturation induced by LPS but not by polyI:C. Control mature DC (‘‘LPS’’ or ‘‘polyI:C’’) were obtained at d 7
after addition of the maturation stimulus at d 6. Control iDC (‘‘iDC’’) were obtained at d 7 without any addition. LVP was added to iDC at d 5 and LPS
or polyI:C at d 6 for 24 h (‘‘LPS on 24 h LVP-treated DC’’ or ‘‘polyI:C on 24 h LVP-treated DC’’). Phenotype and cytokine secretion was analyzed as in
figure 2. (a, c) Phenotypic maturation of LVP-treated DC induced by LPS (a) or polyI:C (c). Profiles of control iDC (dotted line), control mature DC (filled
profile), and DC treated with LVP 24 h before addition of the maturation agent (thick line). Data from one representative experiment out of three. (b,
d) Secretions of cytokines obtained after LPS addition (b) or polyI:C addition (d). Mean secretion6sd of three independent experiments.
doi:10.1371/journal.pone.0000330.g003
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therapy. IFNa was added at d 5 concomitantly with LVP, and LPS
was added at d 6. IFNb was used as control. These DC were then
functionally tested in MLR experiments. As shown in figure 6,
addition of IFNa reversed the action of LVP, and DC incubated
with IFNa and LVP could mature normally after TLR4
engagement and stimulate the production of IFNc by T cells.
IFNb which is not able to block viral replication did not reverse
the action of LVP on maturation of DC induced by TLR4
stimulation.
Figure 4. LVP interferes with TLR4 but not with TLR3 signaling to induce a Th2-type response. (a) LVP interferes with T responses elicited by DC
stimulated by a TLR4 ligand. Control iDC (&) were obtained at d 7 without addition of LPS. Control mature DC (m) were obtained at d 7 after addition
of LPS at d 6. LVP was added to iDC at d 5 and LPS at d 6 for 24 h (#). DC recovered at d 7 were washed, resuspended in RPMI/10% FCS and then
cocultured with T lymphocytes at DC/T cell ratios ranging from 1/10 to 1/40. IL-2, IFNc, IL-5 and IL-13 were measured by ELISA in supernatants of co-
culture. Data represent means6sd of triplicates of one experiment out of eight. (b) LVP does not interfere with TLR3 signaling in DC. Control iDC
(‘‘iDC’’) were obtained at d 7 without addition of polyI:C. Control mature DC (‘‘polyI:C’’) were obtained at d 7 after addition of polyI:C at d 6. LVP was
added to iDC at d 5 and polyI:C at d 6 for 24 h (‘‘polyI:C on 24 h LVP-treated DC’’). DC recovered at d 7 were washed, resuspended in RPMI/10% FCS
and then cocultured with T lymphocytes at DC/T cell ratios ranging from 1/10 to 1/40. IFNc, IL-5 and IL-13 were measured by ELISA in supernatants of
co-culture. Data are shown for 1/40 DC/T cell ratio. Data represent means 6 sd of triplicates of one experiment out of four.
doi:10.1371/journal.pone.0000330.g004
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PLoS ONE | www.plosone.org 7 March 2007 | Issue 3 | e330Figure 5. Purified native lipoproteins do not interfere with DC maturation. Control lipoprotein fraction (IP-LP) with the density of LVP was isolated
from the blood of non-infected donors by ultracentrifugation and immunoprecipitation with an anti-apolipoprotein B antibody and protein A-
microbeads. IP-LP were added to iDC at d 5 and LPS at d 6 for 24 h (‘‘LPS on 24 h IP-LP-treated DC’’). (a) Phenotypic maturation of IP-LP-treated DC
induced by LPS. Profiles of control iDC (dotted line), control LPS-treated DC (filled profile), DC treated with IP-LP 24 h before LPS treatment (thick
line). Data from one representative experiment out of three. (b) Cytokine secretion of LPS-treated DC (opened bars) and DC treated with IP-LP 24 h
before LPS treatment (hatched bars). Mean secretion6sd of three independent experiments. Secretion was normalized to 100% for control LPS-
treated DC. (c) MLR were conducted as described above with LPS-treated DC (opened bars) and 24 h IP-LP-treated DC matured with LPS (hatched
bars). IL-2, IFNc, IL-5 and IL-13 were measured by ELISA in supernatants of co-culture. Secretion of cytokine was normalized to 100% for control LPS-
treated DC. Data are shown for 1/10 DC/T cell ratio.
doi:10.1371/journal.pone.0000330.g005
HCV Alters TLR4 Signaling
PLoS ONE | www.plosone.org 8 March 2007 | Issue 3 | e330MEK and p38-MAPK are involved in the modification
of DC polarization
Many kinases have been shown to play a role in TLR4 maturation
of DC and in the type of T responses they elicit. p38-MAPK is
mainly involved in CD83 induction, CD80 and CD86 upregula-
tion and in TNFa and IL-12 secretions [34,35]. ERK has also
been shown to be phosphorylated upon TLR4 signaling, but its
involvement in TLR4 maturation is still controversial, depending
on the culture system [34,36,37]. We thus examined the effect of
different kinase inhibitors on the ability of DC to stimulate
allogeneic T cells. SB203580 is a specific inhibitor of p38-MAPK
and PD98059 inhibits MEK activation and prevents ERK
phosphorylation. The inhibitors are added at d 5, 30 minutes
before LVP. Non-infected DC treated with the inhibitor of p38-
MAPK before TLR stimulation were not able to stimulate IFNc
secretion by T lymphocytes. Therefore it was not possible to
correlate the action of LVP on DC following LPS stimulation
(absence of induction of IFNc secretion by T cells) to the activation
of this pathway (figure 7a). In contrast, blocking p38-MAPK
pathway in non-infected DC has no significant effect on IL-5 and
IL-13 secretion by T cells. Blocking p38-MAPK pathway in LVP-
treated DC yielded cells that lost their ability to stimulate IL-5 and
IL-13 secretion by T cells (figure 7b). Moreover, blocking MEK-
ERK pathway in DC before LVP incubation and LPS treatment
yielded cells with a restored ability to stimulate IFNc secretion by
T cells without affecting IL-5 and IL-13 production (figure 7c, d).
These data strongly suggest that LVP could influence DC
polarization following TLR4 stimulation by interfering with both
p38-MAPK and MEK/ERK pathways.
DISCUSSION
Several groups have reported that DC from chronically infected
patients may have impaired function in vivo and reduced
maturation capacity ex vivo but this has been challenged by
others who reported that DC from patients could normally
function [38–46]. Although differences in the experimental
procedures could explain this discrepancy, it is likely that DC
remain globally functional during the infection because the
patients appear immunologically competent. Rather, a precise
function of DC could be targeted during the infection that would
specifically impair HCV clearance without affecting global
immunity. In this study, purified LVP were used to demonstrate
that HCV clinical isolate can interfere with the function of DC
from non-infected donors in a discrete manner. LVP interfere with
the TLR4 pathway to generate mature DC that fail to stimulate
production of IFNc by T cells while that of IL-5 and IL-13 was
induced. This Th2 bias observed in these specific conditions is not
in favor of efficient HCV-specific CTL responses and could favor
chronic infection [47–49]. This process can be reversed by IFNa.
Although the precise mechanism for TLR4 pathway interference
by LVP has not yet been identified, the data show that the
engagement of the MEK-ERK and p38-MAPK pathways is
involved in the inhibition of IFNc production and stimulation of
IL-5 and IL-13 synthesis, respectively. This is consistent with
previous studies showing the relative contribution of these two
pathways in DC polarization [35,37,50].
LVP entry into DC leads to incomplete infection cycle that ends
after a transient RNA replication and protein synthesis. LVP
induce various amounts of IFNb production by DC but IFNa was
never detected. We do not have the molecular explanation for the
lack of IFNa production but it is known that monocyte-derived
DC are weak producers of IFNa in response to virus or TLR
stimulation while they produce substantial amounts of IFNb,
probably because the express low levels of interferon regulatory
factor 7 (IRF-7) [51]. Several groups have reported a default in
IFNa production in chronically-infected patients essentially by
looking at the frequency and functionality of plasmacytoid DC
[43–45,52,53]. The effect of LVP on DC was reversed by IFNa in
vitro but to what extend IFNa therapy can prevent the effect of
LVP on DC in vivo remains to be determined.
Infectious agents have evolved strategies that disrupt signaling
pathways normally leading to a protective cellular reaction. TLR3
signaling is not significantly disrupted by LVP and DC appear
even more reactive to the TLR3 ligand polyI:C, leading to
increased secretion of cytokines. This is an additional indication
that LVP do not really infect DC stricto sensus and that the HCV
NS3/4A protease is not expressed at a level allowing an efficient
cleavage of the TLR3 adaptor protein TRIF that would inhibit
TLR3 signaling [25]. Interestingly, the triggering of TLR3 by
dsRNA can result in attenuation of the TLR4 pathway [54]. The
stimulation of TLR3 by HCV dsRNA could theoretically occur
and interfere with the TLR4 pathway but is very unlikely
regarding the weakness of HCV-RNA replication in DC. Direct
interference with TLR4 signaling may impair anti-viral innate
reaction of an infected cell. Interference with TLR2 signaling has
already been reported with HCV protein core in human
monocytes [55]. Although no binding of an HCV protein to
TLR4 has yet been reported, this possibility cannot be excluded.
Lipid remodeling occurs during HCV infection but has not
been studied from an immunological point of view. One aspect of
this remodeling is the presence of LVP in the blood and infected
organs of chronically-infected patients. Although the precise
biochemical composition of LVP has not yet been elucidated,
we and others have described the lipoprotein-like structure of these
particles and their enrichment in triglycerides [5–9]. Because
modified endogenous or exogenous lipids are detected by DC and
can interfere with TLR4 signaling, one intriguing possibility is that
LVP could interfere directly with the TLR4 pathway via some of
its lipid components [23,24,56–58]. Alternatively, LVP could
interfere with TLR4 signaling by modifying the lipid composition
Figure 6. IFNa can restore the ability of LVP-treated DC to induce
IFNc. DC were treated at d 5 with LVP and IFNa or IFNb, and at d 6 with
LPS. MLR were then conducted as described in figure 4 with control
LPS-matured DC, 24 h LVP-treated DC matured with LPS, DC treated
with IFNa and LVP 24 h before LPS addition, and DC treated with IFNb
and LVP 24 h before LPS addition. IFNc was measured in supernatants
of cocultures by ELISA and normalized to 100% for control LPS-treated
DC.
doi:10.1371/journal.pone.0000330.g006
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described for polyunsaturated fatty acids that inhibit the induction
of Th1 responses possibly by insertion in the membrane [59]. The
identification of bioactive lipids that could be involved in the effect
of LVP on DC is in progress but is a complex task because of the
likely possibility that DC may react globally to LVP by integrating
different quality signals delivered by various categories of lipids.
Our preliminary lipidomic analysis confirmed the lipoprotein-like
structure of LVP with some features not found in normal low
density lipoproteins.
A growing list of apparently unrelated molecules can interfere
with TLR4 signaling. Among those are microbial products from
bacteria, viruses, and parasites. This underlines the crucial role of
TLR4 pathway in the innate recognition of pathogens but may
also reveal microbial strategies evolved to facilitate infection.
Physiological relevance of TLR4 signaling interference by LVP
may relate to the origin of these particles and their biochemical
composition. The liver lies directly downstream of the gut and is
therefore constantly exposed to antigens and microbial products
derived from the intestine. Control of liver inflammation and
tolerance to gut-derived antigens (food antigens and commensal
bacteria) are likely to rely, at least in part, on functional
characteristics of hepatic and intestinal antigen presenting cells.
One of these characteristics is the modulation of TLR4 signaling
under the dual pressure of protecting the host from pathogenic
infections and coexistence with the myriad commensal organisms.
Figure 7. MEK and p38-MAPK pathways are involved in DC polarization. (a, b) MLR were conducted as described in figure 4 with control LPS-
matured DC (filled bars), LPS-matured DC pre-treated with SB203580 (SB) (grey bars), 24 h LVP-treated DC matured with LPS (opened bars), DC pre-
treated with SB before LVP incubation and LPS treatment (hatched bars). Secretion of cytokine was normalized to 100% for control LPS-treated DC.
IFNc (a) and IL-5 and IL-13 (b) were measured by ELISA in supernatants of co-culture. Mean6sd are shown. Secretions are in the range of 260–
2600 pg/ml for IFNc, 20–80 pg/ml for IL-5 and 150–370 pg/ml for IL-13. (c, d) MLR were conducted as described in figure 4 with control LPS-matured
DC (filled bars), LPS-matured DC pre-treated with PD98059 (PD) (grey bars), 24 h LVP-treated DC matured with LPS (opened bars), DC pre-treated
with PD before LVP incubation and LPS treatment (hatched bars). Secretion of cytokine was normalized to 100% for control LPS-treated DC. IFNc (c)
and IL-5 and IL-13 (d) were measured by ELISA in supernatants of co-culture.
doi:10.1371/journal.pone.0000330.g007
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commensal bacteria: decreased expression of TLR4, decreased IL-
1 receptor-activated kinase (IRAK) activity, increased expression
of molecules involved in TLR4 negative signaling (Toll-interacting
protein (Tollip), single immunoglobulin IL-1-related receptor
(SIGIRR), peroxisome proliferator-activated receptors c (PPARc)
[60]. Several lines of evidence suggest that the intestine and more
specifically enterocytes can be infected by HCV [11] and that LVP
could derive from both the liver and the intestine [9]. By acting on
TLR4 pathway with LVP, HCV may thus exploit a natural
protective mechanism of the liver and the intestine normally used
to control inflammation and immunity to commensal microorgan-
isms. Accordingly, intestinal inflammation has not been reported
in HCV chronically-infected patients and, for the vast majority of
these patients, no sign of hepatic inflammation can be detected
despite the constant and unquestionable viral production in this
organ.
Regulatory mechanisms that are induced or exploited by
chronic infectious agents may be viewed as an additional way to
balance the host-pathogen interaction whereby host tissue damage
is restricted and pathogen survival is favored. It is tempting to
speculate that interference with TLR4 may be a way in which
a specific form of circulating HCV particles contributes to
chronicity while preventing infected organs from destructive
inflammation and immunity.
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